cancers-logo

Journal Browser

Journal Browser

New Insights in the Role of Myeloid-Derived Suppressor Cells (MDSCs) in Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (31 May 2025) | Viewed by 569

Special Issue Editor


E-Mail Website
Guest Editor
Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
Interests: pprimary myelofibrosis; myeloproliferative neoplasms; vascular endothelial growth factor; immunomodulation; chronic myeloproliferative neoplasms; inflammation; myeloid derived suppressor cells, endothelial cells, myeloid cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, myeloid-derived suppressor cells (MDSCs) have attracted increasing interest as major players in modulating tumor onset and progression of cancer. Although the physiopathology of MDSCs is still partially elusive, there is common agreement that these cells contribute to tumors pathogenesis through their immunosuppressive and pro-neoangiogenic activities. In keeping with this notion, previous studies demonstrated that the frequency of circulating MDSCs represents a reliable predictor of a negative outcome and response to therapy both in solid cancers and in hematological malignancies. Therefore, MDSCs could become potential targets for future therapeutic strategies aimed at favoring their differentiation into mature cells or at counteracting their immunosuppressive and neoangiogenic activity or at inhibiting their ability to migrate from the bone marrow (BM) to peripheral organs.

In this Special Issue of Cancers, we welcome original research articles, reviews and perspectives that provide an overview of the most recent advances involving MDSCs in hematological malignancies and solid cancers. Proposed submission topics could include (but are not limited to) the following: (1) autocrine/paracrine mechanisms that link MDSCs and the chronic inflammatory milieu; (2) involvement of MDSCs in neo-angiogenic processes and metastasis propagation; (3) pre-clinical studies on MDSCs as a therapeutic target; (4) study of mechanisms of mobilization MDSCs from the BM into circulation.

Dr. Rita Campanelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • myeloid-derived suppressor cells
  • hematological malignancies
  • solid cancers
  • inflammation
  • angiogenesis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 758 KiB  
Review
Myeloid-Derived Suppressor Cells (MDSCs) at the Crossroad of Senescence and Cancer
by Giovanna Talarico, Stefania Orecchioni, Paolo Falvo and Francesco Bertolini
Cancers 2025, 17(13), 2251; https://doi.org/10.3390/cancers17132251 - 4 Jul 2025
Viewed by 312
Abstract
The family of myeloid-derived suppressor cells (MDSCs) includes a heterogeneous group of partially immature cells belonging to the myeloid lineage with potent immunosuppressive functions. They might be increased in the peripheral blood of cancer patients and in the microenvironment of cancer lesions, where [...] Read more.
The family of myeloid-derived suppressor cells (MDSCs) includes a heterogeneous group of partially immature cells belonging to the myeloid lineage with potent immunosuppressive functions. They might be increased in the peripheral blood of cancer patients and in the microenvironment of cancer lesions, where they act in suppressing adaptive and innate immune cells, promoting tumor progression, and facilitating resistance to therapy. Several—albeit still limited—studies have shown higher levels of MDSCs in elderly cancer patients, correlating with poorer outcomes and a reduced response to immunotherapies. Thus, MDSCs may serve as biomarkers for prognosis or therapy response in this population, and MDSC-targeting therapies aimed at reducing their number or function may enhance the effectiveness of immunotherapies in older adults. Additionally, a better understanding of MDSCs may help to overcome some age-related barriers in cancer treatments. Full article
Show Figures

Figure 1

Back to TopTop